TLR4 and hepatocellular carcinoma: Besides the activation of the TLR4 signaling pathway in DCs driving the generation of an HCC vaccine [125], Lmdd-MPFG has demonstrated additional immune-modifying effects and the potential to exhibit further effective therapeutic outcomes.